XTL Property Plant And Equipment Net vs Total Assets Analysis

XTLB Stock  USD 2.10  0.22  11.70%   
XTL Biopharmaceutica financial indicator trend analysis is more than just analyzing XTL Biopharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XTL Biopharmaceuticals is a good investment. Please check the relationship between XTL Biopharmaceutica Property Plant And Equipment Net and its Total Assets accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Property Plant And Equipment Net vs Total Assets

Property Plant And Equipment Net vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XTL Biopharmaceuticals Property Plant And Equipment Net account and Total Assets. At this time, the significance of the direction appears to have totally related.
The correlation between XTL Biopharmaceutica's Property Plant And Equipment Net and Total Assets is 0.99. Overlapping area represents the amount of variation of Property Plant And Equipment Net that can explain the historical movement of Total Assets in the same time period over historical financial statements of XTL Biopharmaceuticals Ltd, assuming nothing else is changed. The correlation between historical values of XTL Biopharmaceutica's Property Plant And Equipment Net and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Net of XTL Biopharmaceuticals Ltd are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Property Plant And Equipment Net i.e., XTL Biopharmaceutica's Property Plant And Equipment Net and Total Assets go up and down completely randomly.

Correlation Coefficient

0.99
Relationship DirectionPositive 
Relationship StrengthVery Strong

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Total Assets

Total assets refers to the total amount of XTL Biopharmaceutica assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in XTL Biopharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from XTL Biopharmaceutica's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XTL Biopharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
At present, XTL Biopharmaceutica's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 3.9 M, whereas Selling General Administrative is forecasted to decline to about 697.3 K.

XTL Biopharmaceutica fundamental ratios Correlations

1.0-0.27-0.980.740.840.87-0.10.99-0.420.980.970.430.150.050.940.86-0.580.970.230.210.980.95-0.570.99-0.06
1.0-0.24-0.980.690.810.85-0.080.99-0.430.970.960.430.10.060.940.86-0.560.970.210.250.990.95-0.550.99-0.12
-0.27-0.240.26-0.36-0.35-0.440.03-0.230.19-0.35-0.31-0.2-0.430.02-0.19-0.260.68-0.160.15-0.06-0.19-0.210.72-0.23-0.32
-0.98-0.980.26-0.72-0.8-0.850.08-0.980.36-0.97-0.96-0.36-0.12-0.14-0.9-0.850.6-0.95-0.23-0.23-0.98-0.910.59-0.980.14
0.740.69-0.36-0.720.690.730.010.71-0.280.720.720.290.29-0.030.670.64-0.490.70.5-0.140.690.68-0.490.710.14
0.840.81-0.35-0.80.690.890.020.82-0.220.840.830.220.46-0.080.680.61-0.670.740.10.150.80.71-0.650.820.3
0.870.85-0.44-0.850.730.89-0.250.87-0.150.910.930.160.570.070.680.87-0.810.740.030.060.830.71-0.790.870.36
-0.1-0.080.030.080.010.02-0.25-0.08-0.28-0.13-0.20.28-0.5-0.380.0-0.350.08-0.070.440.3-0.040.00.06-0.08-0.28
0.990.99-0.23-0.980.710.820.87-0.08-0.330.980.980.330.130.10.890.87-0.60.940.190.221.00.9-0.581.0-0.11
-0.42-0.430.190.36-0.28-0.22-0.15-0.28-0.33-0.31-0.22-1.00.360.55-0.66-0.280.01-0.49-0.4-0.42-0.36-0.650.04-0.330.13
0.980.97-0.35-0.970.720.840.91-0.130.98-0.310.990.310.260.180.860.89-0.710.910.160.180.960.88-0.70.98-0.02
0.970.96-0.31-0.960.720.830.93-0.20.98-0.220.990.220.310.210.820.91-0.70.890.130.140.960.84-0.680.980.01
0.430.43-0.2-0.360.290.220.160.280.33-1.00.310.22-0.36-0.540.660.28-0.020.490.40.420.360.65-0.060.33-0.13
0.150.1-0.43-0.120.290.460.57-0.50.130.360.260.31-0.360.22-0.10.28-0.59-0.02-0.25-0.310.05-0.07-0.590.130.81
0.050.060.02-0.14-0.03-0.080.07-0.380.10.550.180.21-0.540.22-0.10.13-0.210.03-0.03-0.350.09-0.11-0.20.1-0.33
0.940.94-0.19-0.90.670.680.680.00.89-0.660.860.820.66-0.1-0.10.75-0.350.980.370.280.911.0-0.350.89-0.22
0.860.86-0.26-0.850.640.610.87-0.350.87-0.280.890.910.280.280.130.75-0.650.790.10.120.840.77-0.630.870.08
-0.58-0.560.680.6-0.49-0.67-0.810.08-0.60.01-0.71-0.7-0.02-0.59-0.21-0.35-0.65-0.410.15-0.25-0.55-0.391.0-0.6-0.36
0.970.97-0.16-0.950.70.740.74-0.070.94-0.490.910.890.49-0.020.030.980.79-0.410.320.210.950.98-0.40.94-0.22
0.230.210.15-0.230.50.10.030.440.19-0.40.160.130.4-0.25-0.030.370.10.150.32-0.180.210.350.120.19-0.27
0.210.25-0.06-0.23-0.140.150.060.30.22-0.420.180.140.42-0.31-0.350.280.12-0.250.21-0.180.240.28-0.250.22-0.19
0.980.99-0.19-0.980.690.80.83-0.041.0-0.360.960.960.360.050.090.910.84-0.550.950.210.240.92-0.531.0-0.19
0.950.95-0.21-0.910.680.710.710.00.9-0.650.880.840.65-0.07-0.111.00.77-0.390.980.350.280.92-0.390.9-0.18
-0.57-0.550.720.59-0.49-0.65-0.790.06-0.580.04-0.7-0.68-0.06-0.59-0.2-0.35-0.631.0-0.40.12-0.25-0.53-0.39-0.58-0.36
0.990.99-0.23-0.980.710.820.87-0.081.0-0.330.980.980.330.130.10.890.87-0.60.940.190.221.00.9-0.58-0.11
-0.06-0.12-0.320.140.140.30.36-0.28-0.110.13-0.020.01-0.130.81-0.33-0.220.08-0.36-0.22-0.27-0.19-0.19-0.18-0.36-0.11
Click cells to compare fundamentals

XTL Biopharmaceutica Account Relationship Matchups

XTL Biopharmaceutica fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets7.2M6.5M6.6M4.2M2.4M2.3M
Total Stockholder Equity7.0M6.2M5.3M4.0M2.2M2.1M
Common Stock Shares Outstanding5.1M514.2M615.5M544.9M544.9M572.2M
Liabilities And Stockholders Equity7.2M6.5M6.6M4.2M2.4M2.3M
Total Liab232K254K1.3M187K206K195.7K
Other Current Liab231K252K229K185K205K194.8K
Total Current Liabilities232K254K231K187K206K195.7K
Other Liab1.0M465K2.6M1.1M1.2M1.3M
Net Debt(4.5M)(3.6M)(3.0M)(2.1M)(1.4M)(1.5M)
Retained Earnings(153.9M)(154.7M)(155.1M)(156.5M)(158.2M)(166.2M)
Cash4.5M3.6M3.0M2.1M1.4M1.3M
Cash And Short Term Investments6.7M6.0M6.1M3.7M2.0M1.9M
Short Term Investments2.3M2.4M3.2M1.6M605K574.8K
Non Current Liabilities Total2.7M0.01K2.6M1.1M2K
Other Current Assets102K79K110K85K40K68K
Total Current Assets6.8M6.1M6.2M3.8M2.0M1.9M
Net Tangible Assets6.6M3.2M5.0M3.6M4.2M4.6M
Net Invested Capital7.0M6.2M5.3M4.0M2.2M4.2M
Net Working Capital6.6M5.9M6.0M3.6M1.8M1.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
(0.03)
Return On Assets
(0.14)
Return On Equity
(0.13)
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.